Treatment with acarbose, an alpha-glucosidase inhibitor, reduces increased albumin excretion in streptozotocin-diabetic rats.
1. We examined the effect of the alpha-glucosidase inhibitor acarbose on urinary albumin excretion (UAE) in streptozotocin diabetic rats. 2. Treatment with acarbose for 8 weeks after induction of diabetes prevented the significant increase in UAE observed in untreated diabetic rats relative to nondiabetic controls. 3. Acarbose significantly reduced integrated glycemia, which correlated with albumin excretion rates, and exerts a salutary effect on diabetic renal dysfunction.
Cohen
M P
MP
Institute for Metabolic Research, University City Science Center, Philadelphia, PA, USA.
Vasselli
J R
JR
Neuman
R G
RG
Witt
J
J
D020909:Acarbose; D000419:Albuminuria; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005959:Glucosidases / Q000187:drug effects*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin / Q000494:pharmacology; D013997:Time Factors; D014312:Trisaccharides / Q000627:therapeutic use*
D001786:Blood Glucose; D004791:Enzyme Inhibitors; D014312:Trisaccharides; D013311:Streptozocin; D005959:Glucosidases; D020909:Acarbose